


Edited by Michael J. Sofia and Zhengqiang Wang

Trends in Antiviral Drug Development

Volume 2

Series Editors: János Fischer, Christian Klein,
Wayne E. Childers, David P. Rotella



Trends in Antiviral Drug Development

Trends in Drug Discovery

Trends in Antiviral Drug Development

Edited By

Dr. Michael J. Sofia
Arbutus Biopharma
701 Veterans Circle
Warminster
PA 18974, USA

Dr. Zhengqiang Wang
University of Minnesota
312 Church St. SE
Minneapolis
MN 55455, USA

WILEY-VCH

Editors

Dr. Michael J. Sofia

Arbutus Biopharma
701 Veterans Circle
Warminster
PA 18974, USA

Dr. Zhengqiang Wang

University of Minnesota
312 Church St. SE
Minneapolis
MN 55455, USA

Cover Images © max.ku/Shutterstock,
© Kateryna Kon/Shutterstock

■ All books published by **WILEY-VCH** ((or **Ernst & Sohn**)) are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2025 Wiley-VCH GmbH, Boschstraße 12, 69469 Weinheim, Germany ((or Ernst & Sohn GmbH, Rotherstraße 21, 10245 Berlin, Germany))

All rights reserved (including those of translation into other languages, text and data mining and training of artificial technologies or similar technologies). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 9783527353019

ePDF ISBN: 9783527845101

ePub ISBN: 9783527845095

oBook ISBN: 9783527845088

Set in 9.5/12.5 STIX Two Text by
Lumina Datamatics

Contents

Preface xv

Introduction: Successes and Challenges in Antiviral Drug Development 1

Zhengqiang Wang and Michael J. Sofia

Introduction 1

Antiviral Drugs Targeting Human Herpesviruses 2

Antiviral Drugs Targeting Human Immunodeficiency Virus 4

Drugs Targeting Reverse Transcriptase 4

Drugs Targeting Protease 6

Drugs Targeting Integrase Strand Transfer 7

Drugs Targeting Viral Entry 7

Drugs Targeting Viral Capsid 8

Antiviral Drugs Targeting Hepatitis B Virus 9

Antiviral Drugs Targeting Hepatitis Delta Virus 10

Antiviral Drugs Targeting Hepatitis C Virus 11

Antiviral Drugs Targeting Acute RNA Respiratory Viruses 11

Drugs Targeting Human Influenza Viruses 11

Drugs Targeting SARS-CoV-2 14

New Trends and Challenges in Antiviral Drug Development 15

References 16

Part I Human Herpes Viruses 31

1 Letemovir for the Prevention of CMV Infection in Transplant Recipients 33

Peter Lischka and Holger Zimmermann

1.1 Background 33

1.1.1 Cytomegalovirus 33

1.1.2 Immunocompromised Patients 34

1.1.3 Patient Groups with a High Risk for CMV Complications 34

1.1.4 Available CMV Treatments Before Letemovir 35

1.1.4.1 Antiviral Drugs 35

1.1.4.2	Dominant Treatment Strategies	37
1.1.4.3	Unmet Medical Need	38
1.2	Discovery Phase	38
1.3	Preclinical Characterization	39
1.3.1	Antiviral Potency/Selectivity/Inhibitory Profile	39
1.3.1.1	<i>In Vitro</i> Potency Versus Laboratory CMV Strains	39
1.3.1.2	<i>In Vitro</i> Potency Versus Clinical CMV Isolates and Resistance-breaking Profile	40
1.3.1.3	<i>In Vivo</i> Efficacy (Xenotransplant Model)	41
1.3.1.4	<i>In Vitro</i> Antiviral Specificity	42
1.3.1.5	Other Characteristics of Letemovir's Inhibitory Profile	43
1.3.1.6	Summary	43
1.4	Mechanism of Action Studies	43
1.4.1	Target Identification	43
1.5	Terminase Inhibitors	46
1.5.1	Previous and Contemporary Drug Candidates Targeting the Terminase Complex	46
1.5.2	Letemovir: Same Target, Different Interaction	49
1.5.3	Advantages of Terminase Inhibitors	49
1.6	Preclinical Safety Evaluation	50
1.7	Clinical Development and MAA/NDA Submission	51
1.7.1	Regulatory Support for Clinical Development	51
1.7.2	Phase 1	51
1.7.2.1	Drug–Drug Interaction Studies	51
1.7.2.2	Special Populations	51
1.7.2.3	IV Formulation	52
1.7.3	Clinical Proof-of-concept	52
1.7.3.1	Phase 2a Clinical Trial (AIC001-2-001)	52
1.7.3.2	Emergency IND Treatment of a Lung Transplant Patient with Multiresistant CMV Disease	53
1.7.3.3	Credentials Established	54
1.7.4	Letemovir for CMV Prophylaxis in HSCT Patients	55
1.7.4.1	Phase 2b: First Prophylaxis Trial in HSCT Patients	55
1.7.4.2	Phase 3 CMV Prophylaxis Trial in HSCT Patients	55
1.7.4.3	Marketing Approval in HSCT Recipients	57
1.7.4.4	Further Clinical Development and Real-world Data	57
1.7.4.4.1	Phase 3 Trial for Extension of the Prophylaxis Period	59
1.7.4.4.2	Follow-up Trials in Specific Populations	59
1.7.5	Letemovir for CMV Prophylaxis in KT Patients	60
1.7.5.1	Phase 3 Noninferiority Trial in KT Recipients	61
1.7.5.2	Marketing Approval in KT Recipients	61
1.7.5.3	Further Clinical Development and Real-world Data	62
1.8	Drug Resistance	62
1.8.1	Genetic Characterization of Letemovir Resistance	62
1.9	Letemovir Resistance in Clinical Trials	64
1.10	Real-world Resistance	65

1.11	Outlook for Letemovir	65
	Acknowledgments	66
	References	66
2	Discovery and Development of the Helicase–Primase Inhibitor Pritelivir for the Treatment of Immunocompromised Patients with Resistant HSV Infection	75
	<i>Alexander Birkmann</i>	
2.1	HSV Virology and Disease	75
2.2	Treatment	76
2.3	Resistant Infections	79
2.4	Pritelivir Discovery and Target Identification	80
2.5	Nonclinical Data	82
2.5.1	<i>In Vitro</i> Studies	82
2.5.2	<i>In Vivo</i> Studies	83
2.5.2.1	Guinea Pig Model for Genital HSV-2 Infection	83
2.5.2.2	Mouse Model for HSE	84
2.5.2.3	Pritelivir in Immunocompromised Mouse Model	85
2.6	Clinical Data	85
2.6.1	Phase 1 Program	85
2.6.2	Genital HSV	86
2.6.3	Resistant Infections	88
2.7	Pritelivir Resistance	92
2.8	Conclusion and Outlook	92
	References	93
	Part II Immunodeficiency Virus	101
3	The Discovery and Early Development of the HIV-1 Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)	103
	<i>Sherene Min, Soong Hoon Kim, Mark Underwood, Brian Wynne, William Spreen</i>	
3.1	Introduction	103
3.2	Medicinal Chemistry	105
3.2.1	Discovery of S/GSK1349572 (DTG)	105
3.2.1.1	Evolution of the Chemical Structure Leading to DTG	105
3.3	Virology	111
3.3.1	<i>In Vitro</i> Studies Indicated Robust Efficacy and High Barrier to Resistance of DTG	111
3.4	Clinical Development	115
3.4.1	PK Studies Supported Once-daily 50 mg Dosing of DTG	115
3.4.2	Clinical Studies in People Living with HIV-1	116
3.4.3	Clinical Studies in Individuals with Prior Treatment Failure	119
	Acknowledgments	120
	References	120

4	The Discovery and Development of Islatravir (4'-Ethynyl-2'-fluoro-2'-deoxyadenosine [EFdA], MK-8591)	127
	<i>Alexa A. Snyder, Xin Wen, Eleftherios Michailidis, Karen A. Kirby, Hiroaki Mitsuya, Stefan G. Sarafianos</i>	
4.1	Introduction	127
4.2	HIV Replication Cycle	128
4.3	Structure and Function of HIV RT	128
4.4	DNA Synthesis by RT	130
4.5	RT Inhibitor Classes	132
4.6	EFdA Development	133
4.6.1	4'-Ethynyl Ribose Modifications	134
4.6.2	2-Fluoro Adenosine Modifications	135
4.6.3	3'-Hydroxy Ribose Modification	136
4.7	EFdA: A Compound with 4'-Ethynyl, 2-Fluoro, and 3'-Hydroxy Modifications	137
4.7.1	Effects of the 4'-Ethynyl Modification on EFdA	137
4.7.2	Effects of the 2'-Fluoro Modification on EFdA	140
4.7.3	Effects of the 3'-Hydroxy Modification on EFdA	141
4.7.3.1	Mechanisms of Inhibition: EFdA	141
4.7.3.1.1	Biochemical Mechanisms of Inhibition	141
4.7.3.1.2	Structural Mechanisms of Inhibition	142
4.8	Mechanism of Resistance/Hypersusceptibility to EFdA	144
4.8.1	Mechanisms of Viral Resistance to EFdA	144
4.8.2	Mechanisms of Viral Hypersusceptibility to EFdA	146
4.8.3	Combination Therapies with EFdA	146
4.8.4	Synthesis Advances	148
4.9	Animal Studies	149
4.9.1	EFdA Pharmacokinetic Studies in Rodents	149
4.9.2	EFdA Antiviral Activity in Humanized Mice	150
4.9.3	EFdA Antiviral Activity in Rhesus Macaques	151
4.9.4	EFdA Long-acting Activity in Various Animals	152
4.10	Clinical Trials	160
4.11	Long-acting Methods of Delivery for EFdA Treatment	160
4.12	NRTTIs as a Drug Class	166
	References	166

Part III Hepatitis Viruses 185

5	Discovery of the RNA Interference Therapeutic Imdusiran, a GalNAc-conjugated siRNA	187
	<i>Emily Thi</i>	
5.1	Introduction	187
5.2	Comparison of Preclinical Anti-HBV Efficacy Between Lipid Nanoparticle-encapsulated and GalNAc-conjugated siRNA	188
5.3	Comparison of Tetravalent Versus Trivalent GalNAc Ligands	190

5.4	siRNA Selection: Comparison of siRNA Activity Against HBsAg and HBx Targets	191
5.5	Imdusiran Design and Preclinical Characterization	192
5.5.1	Abrogation of siRNA Immunostimulatory Potential	192
5.5.2	Imdusiran siRNA Target Site Sequence	193
5.6	Imdusiran Antiviral Activity	197
5.6.1	Imdusiran Antiviral Activity in Primary Mouse and Human Hepatocyte HBV Models	197
5.6.2	Imdusiran <i>In Vivo</i> Antiviral Activity	199
5.7	Imdusiran Combination Treatment	200
5.7.1	Imdusiran Combination with Standard of Care and Investigational Agents	200
5.8	Perspectives	203
	References	206
6	Discovery and Development of ARO-HBV/JNJ-3989	211
	<i>Christine I. Wooddell, Oliver Lenz, Thomas Schlupe, Man-Fung Yuen, Michael Biermer</i>	
6.1	Introduction	211
6.1.1	Chronic Hepatitis B Virus Infection	211
6.1.1.1	HBV Structure and Associated Molecular and Cellular Biology	212
6.1.1.1.1	Clinical Course of HBV Infection	215
6.2	Development of RNAi Therapeutic ARO-HBV/JNJ-73763989 (JNJ-3989)	216
6.2.1	RNAi as a Therapeutic Modality	216
6.2.2	Use of siRNA to Treat HBV Infection	216
6.2.2.1	JNJ-3989 siRNAs Have Broad Cross-reactivity to HBV Genotypes and HBV Transcripts	217
6.2.2.1.1	Reduction of Serum HBsAg, HBeAg, and HBV DNA in Mouse Model of Chronic HBV Infection	218
6.3	Pharmacokinetics and Safety of JNJ-3989 in Humans	218
6.4	Clinical Studies in Chronically HBV-infected Patients	220
6.4.1	Direct Antiviral Treatment Approach with JNJ-3989-based Regimens	220
6.4.1.1	Pharmacological Response to JNJ-3989 with Short-term Treatment	220
6.4.1.2	REEF-1 Clinical Study	225
6.4.1.3	REEF-2 Clinical Study	232
6.4.2	Combination Approaches of JNJ-3989 with Immune Modulation	233
6.4.2.1	PENGUIN Clinical Study	234
6.4.2.2	REEF-IT Clinical Study	234
6.4.3	HBsAg Targeting siRNA JNJ-3989 in Chronic Hepatitis D	236
6.4.3.1	REEF-D Clinical Study	236
6.5	Discussion and Perspectives	238
	References	239

7	The Discovery and Development of Sofosbuvir as the Backbone of HCV Curative Therapies	247
	<i>Michael J. Sofia</i>	
7.1	Introduction	247
7.2	Identification of the 2'- α -F, 2'- β -C-Methyl Cytidine Nucleoside PSI-6130	248
7.3	Identification of the 3',5'-Diisobutyrate Ester Prodrug RG7128 and Clinical Proof-of-concept	250
7.4	Development of the 5'-Phosphoramidate Uridine Nucleotide Prodrug for Liver Targeting and Clinical Proof-of-concept	251
7.5	Sofosbuvir: The Backbone of HCV Curative Therapies	255
7.6	Conclusion	261
	References	261
8	The Discovery and Development of Harvoni® and Epclusa®: Ending the Interferon Era; Curing All Hepatitis C Genotypes	267
	<i>John O. Link</i>	
8.1	Cure	267
8.2	Introduction	267
8.3	The Discovery of Ledipasvir [13–15]	270
8.4	Early Development of Ledipasvir	278
8.5	Ledipasvir/Sofosbuvir STR Clinical Trial Results and Real-world Effectiveness	280
8.6	Initiation of a Pangenotypic NS5A Inhibitor Program	283
8.7	Discovery of the Pangenotypic NS5A Inhibitor Velpatasvir [40–42]	284
8.8	The Development of Velpatasvir	293
8.9	Clinical Trial Efficacy and Real-world Effectiveness with the Pangenotypic Sofosbuvir/Velpatasvir STR	297
8.10	Conclusion	300
	Acknowledgment	300
	Compliance with Ethical Standards	301
	References	301

Part IV Respiratory Viruses 307

9	Presatovir: A Once-daily Oral Respiratory Syncytial Virus Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus Infection in Adults and Infants	309
	<i>Richard L. Mackman, Jason Chien, Dustin S. Siegel</i>	
9.1	Introduction to Respiratory Syncytial Virus	309
9.2	Discovery of Presatovir	311
9.2.1	Lead Identification	311

9.2.2	Lead Optimization	313
9.3	Pharmacological Profiling	317
9.3.1	Mechanism of Action Studies	317
9.3.2	RSV Animal Models	319
9.3.3	Spectrum of Activity	320
9.4	Pharmacokinetics	320
9.4.1	Preclinical Intravenous and Oral Pharmacokinetics	320
9.4.2	Lung Distribution Properties	322
9.4.3	Human Dose Prediction	323
9.5	Clinical Development	323
9.5.1	Regulatory Considerations	323
9.5.2	Phase 1 Program	324
9.5.3	Phase 2 Program	325
9.5.4	Treatment Emergent Mutations	327
9.6	Conclusion	328
	References	328

10 Remdesivir for the Treatment of COVID-19 and Other Viral Infections with Pandemic Potential

Tomas Cihlar, Meghan S. Vermillion, Joe Llewellyn, Charlotte Hedskog, Richard L. Mackman

10.1	Introduction	333
10.2	Discovery of Remdesivir	335
10.2.1	Discovery of 1'-Modified C-Nucleosides	335
10.2.2	Phosphoramidate Prodrug Optimization for RSV	336
10.2.3	Synthesis	338
10.3	Pharmacokinetics	339
10.3.1	<i>In Vitro</i> Metabolism	339
10.3.2	<i>In Vivo</i> Pharmacokinetics	341
10.3.3	<i>In Vivo</i> Lung Metabolism	342
10.3.4	Oral Delivery and the Discovery of Obeldesivir	343
10.4	Antiviral Pharmacology	343
10.4.1	Mechanism of Action	343
10.4.2	Spectrum of Antiviral Activity	344
10.4.3	Preclinical Antiviral Efficacy in Animal Models	346
10.5	Clinical Studies	348
10.5.1	Phase 1	348
10.5.2	Ebola Clinical Development	349
10.5.3	COVID-19 Clinical Development	349
10.5.4	Obeldesivir Clinical Development	351
10.6	Antiviral Resistance	351
10.7	Summary	353
	Acknowledgments	355
	References	355

11	Discovery and Clinical Development of Ensitrelvir: An Oral SARS-CoV-2 3CL Protease Inhibitor for the Treatment of COVID-19	365
	<i>Yuki Tachibana, Ryosuke Shimizu, Haruaki Nobori, Yuko Tsuge, Masaharu Shinkai</i>	
11.1	Introduction	365
11.2	Discovery of Ensitrelvir	369
11.3	Antiviral Activity of Ensitrelvir	374
11.3.1	<i>In Vivo</i> Antiviral Efficacy of Ensitrelvir	376
11.3.1.1	Delayed-treatment Model	376
11.3.1.2	Pharmacokinetics and Pharmacodynamics	378
11.3.2	Pharmacokinetics	380
11.3.2.1	Pharmacokinetic Profiles	380
11.3.2.2	Effect of Food	381
11.3.2.3	Drug–Drug Interactions	382
11.3.3	Clinical Trial of Ensitrelvir	383
11.4	Outlook	384
11.5	Conclusions	384
	References	385
12	Discovery and Development of VV116: A Novel Oral Nucleoside Anti-SARS-CoV-2 Drug	389
	<i>Huilong Wang, Yuanchao Xie, Tianwen Hu, Jingshan Shen</i>	
12.1	Introduction	389
12.2	Discovery	390
12.3	Synthesis	394
12.4	Preclinical Study	396
12.4.1	Virology	396
12.4.2	Mechanism of Antiviral Activity of VV116	398
12.4.3	Preclinical Pharmacokinetics	398
12.4.4	Toxicology	400
12.5	Clinical Study	400
12.5.1	Pharmacokinetics	400
12.5.2	Safety and Tolerability	402
12.5.3	Phase III Studies	402
12.6	Future Direction	403
12.7	Conclusions	404
	References	405
13	Molnupiravir	411
	<i>Richard K. Plemper</i>	
13.1	Introduction	411
13.2	Mechanism of Antiviral Activity	412
13.3	Potential for NHC-TP Incorporation into the Host Genome	413
13.4	Risk of Molnupiravir-enhanced Viral Evolution	415
13.5	Therapeutic Benefit of Molnupiravir	416
13.6	Conclusions	418

Acknowledgments	419
Conflict of Interest	419
References	419

Part V Tropical Disease Viruses 425

14	Development of a Novel Class of Highly Potent Dengue Virus Inhibitors: From Hit to the Clinical Candidate Mosnodenvir	427
	<i>Suzanne J. F. Kaptein, Bart Kesteleyn, Olivia Goethals, Oliver Ackaert, Dorothee Bardiot, Dominik Kiemel, Guillermo Herrera-Taracena, Ralf Bartenschlager, Marnix Van Loock, Tim H. M. Jonckers, Arnaud Marchand, Patrick Chaltin, Johan Neyts</i>	
14.1	Introduction	427
14.2	Discovery and Optimization of New Dengue Drugs for Prophylaxis	429
14.2.1	Identification of the Hit CIM020928	429
14.2.2	Early SAR Exploration	431
14.2.3	Early Evaluation of <i>In Vitro</i> ADME-Tox and <i>In Vivo</i> Pharmacokinetic Properties	433
14.2.4	Improving Oral Bioavailability	433
14.2.5	Identification of Preclinical Candidates	434
14.2.6	Identification of the Clinical Candidate	435
14.3	Biological Characterization	436
14.4	Efficacy of Mosnodenvir in Preclinical DENV Infection Models	438
14.5	Safety Profile and Pharmacokinetics of Mosnodenvir in Humans	440
14.6	Conclusions	441
	Acknowledgments	441
	References	441

Part VI Orthopoxvirus 445

15	Discovery and Development of Brincidofovir	447
	<i>E. Randall Lanier, Scott Foster, Graciela Andrei</i>	
15.1	Discovery	447
15.1.1	Key Points	448
15.2	Summary of Current and Potential Indications for BCV	449
15.3	Antiviral Activity	450
15.3.1	Antiviral Activity Against Double-stranded DNA Viruses	450
15.3.1.1	Antiviral MOA	451
15.3.1.1.1	Viruses with Viral DNA Polymerases	451
15.3.1.1.2	Viruses Without Viral DNA Polymerases	452
15.3.2	Antiviral Activity Against RNA Viruses	453
15.3.2.1	Ebola	453
15.3.2.2	SARS-CoV-2	454

15.4	Key Clinical Pharmacology and Safety Considerations	454
15.4.1	Metabolism and Animal Models	456
15.5	Clinical Development	457
15.5.1	Poxviruses	457
15.5.1.1	Introduction to BCV Animal Models	459
15.5.1.2	Rabbitpox Model	460
15.5.1.3	Mousepox Model	461
15.5.1.4	Scaling to Humans	461
15.5.1.5	Vaccine Interaction Studies	462
15.5.1.6	Resistance	462
15.5.1.7	Other Poxviruses (VACV, Mpox)	462
15.5.1.7.1	Vaccinia Virus	462
15.5.1.7.2	Monkeypox Virus	463
15.5.2	Adenovirus	463
15.5.2.1	Clinical Experience with Oral BCV for AdV	464
15.5.2.2	Adenovirus Type and Response to BCV	466
15.5.2.3	AdV Resistance to BCV	467
15.5.2.4	ATHENA (IV BCV for AdV)	468
15.5.3	Cytomegalovirus	469
15.5.3.1	Clinical Experience with Oral BCV for CMV	469
15.5.3.2	CMV Resistance to BCV	471
15.5.4	Polyomaviruses	474
15.5.4.1	BKV Clinical Data with CDV/BCV	474
15.5.4.2	JCV Clinical Data with CDV/BCV	475
15.6	Neurodegenerative Diseases	476
15.6.1	EBV and Multiple Sclerosis	476
15.6.2	HSV and Alzheimer's Disease	477
15.6.3	HHV-6	478
15.7	Antiproliferative Activity	478
15.7.1	Papillomavirus-associated Tumors	479
15.7.1.1	<i>In Vitro</i> Activity Against Papillomavirus-associated Tumors and MOA	479
15.7.1.2	Animal Studies	480
15.7.1.3	Clinical Studies	480
15.7.2	EBV-associated Tumors	481
15.7.3	Glioblastoma	482
15.7.4	Antiproliferative MOA	483
15.8	Summary and Future Directions	483
	Acknowledgments	485
	References	485

Preface

As practitioners in the field of antiviral drug discovery and development, we collectively have observed and contributed to the field for over 47 years, published over 130 papers on antiviral research, introduced 17 antiviral drugs into development, and discovered and developed the first direct-acting antiviral drug to cure a viral disease. We have seen major progress in both treating and curing viral diseases and have observed how advancements in new science and technologies helped expand our knowledge of viruses and provided new insights into how to develop innovative antiviral therapeutics. Yet, we have also seen how cunning viruses are in the way they attack the human host and coopt the human body's own biological processes to survive. We have seen how drug hunters constantly battle to innovate and find ways to combat viruses as they continually change and adapt to the environment around them, and as new viruses emerge by jumping from species to species. Consequently, it was our desire to publish a book that would highlight some of the recent advances in the field of antivirals that occurred over the last 20 years and provide to those who are interested in learning about how antivirals have been developed a window into the thinking and processes used by the scientists who made these discoveries. This book delves into the discovery of drugs to treat HIV, CMV, HSV, VARV, RSV, and SARS-CoV-2, and the breakthrough drugs that cured HCV. It also introduces siRNA therapeutics as a new antiviral modality and the drug candidates in the clinic that are progressing toward achieving an HBV cure. Our hope is that the stories told here in *Trends in Antiviral Drug Development* would expand the readers' understanding of what it takes to develop a drug to treat viral diseases and encourage new ideas and approaches to combat the ever-expanding universe of viral infections.

Michael J. Sofia, PhD, FRSC
Zhengqiang Wang, PhD

Introduction

Successes and Challenges in Antiviral Drug Development

Zhengqiang Wang¹ and Michael J. Sofia²

¹ Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA

² Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA

Introduction

Viral infections have had a profound impact on socioeconomics and life expectancy of human societies throughout human history [1–7]. However, the discovery and development of specific antiviral drugs to treat viral diseases has a relatively short history, largely concomitant with the advent of modern biomedical sciences. Specifically, the FDA approval of idoxuridine (IDU) [8] in 1963, a deoxynucleoside analog first synthesized by Prusoff in 1958 [9], ushered in the era of direct-acting antivirals (DAAs). Since then, many antiviral drugs and drug combinations have been successfully developed and marketed [10], which have largely mitigated many human viral pathogens that historically plagued human societies. Not surprisingly, most of these drugs target viruses that cause chronic infections and/or establish latency. Human immunodeficiency virus (HIV), in particular, has been at the center of antiviral drug development and drug regimen evolution, with dozens of single agents and fixed-dose combinations (FDCs) approved, spanning a wide range of compound classes and molecular targets [11, 12]. The everlasting needs to prevent infection, enhance drug accessibility, and improve adherence have also spurred developments in pre-exposure prophylaxis (PrEP) [13, 14], regimen simplification [15–17], and long-acting injectables (LAIs) [18–20]. Prior to HIV, the earliest antiviral drugs mostly targeted human herpesviruses (HHVs), including herpes simplex virus (HSV), varicella zoster virus (VZV), and human cytomegalovirus (HCMV). Other major chronic viruses targeted by various small-molecule antiviral drugs include hepatitis B virus (HBV) and hepatitis C virus (HCV), both causing viral hepatitis and increasing risk of hepatocarcinoma. Although current antiviral drugs typically do not clear HIV, HBV, or HHVs, the development of DAAs to successfully

cure HCV represents a major breakthrough [21, 22] in antiviral therapy and provides hope that further development in antiviral drugs could eventually lead to the functional cure of other challenging viral infections. Widespread and seasonal acute viral infections, such as influenza virus, respiratory syncytia virus (RSV), and SARS-CoV-2, have also caused major mortality and morbidity, and have been targeted by successful and ongoing antiviral drug development efforts.

Antiviral Drugs Targeting Human Herpesviruses

HHVs, a family of eight large DNA viruses, are highly prevalent within human populations [23]. While primary infections are generally associated with low risk, these viruses are all capable of establishing lifelong latency. In immunocompromised individuals, the reactivation of the latent infection causes high morbidity and mortality. Among HHVs, α -herpesviruses HSV and VZV, and β -herpesvirus HCMV, have received particular attention in drug discovery.

The vast majority, if not all, of the earliest HHV drugs belonged to four distinct subclasses of nucleos(t)ide analogs (Table 1): (1) C-5 substituted thymidine analogs, including IDU [8, 24, 25], trifluridine (TFT) [26], and brivudine (BVDU) [27], where the C-5 substituent is mechanistically important by disrupting base pairing; (2) marine sponge *tectitethya crypta* spongonucleoside [28] vidarabine (ara-A) [29], which contains D-arabinose rather than D-ribose; (3) acyclic nucleosides [30] aciclovir (ACV), penciclovir (PCV), and ganciclovir (GCV); and (4) acyclic nucleoside phosphonate (ANP) [31] cidofovir. Intracellularly, all nucleoside analogs (the first three subclasses) are converted to monophosphate (MP) by a virally encoded kinase, and then further phosphorylated by cellular kinases to the active form triphosphate (TP). ANP cidofovir bypasses the function of viral kinase as the MP is already chemically installed, but still uses cellular kinases to form the active TP. Early mechanistic studies showed that these TPs can stop viral DNA synthesis via competitive viral polymerase inhibition or by getting incorporated into the DNA and acting as chain terminators. Of these nucleos(t)ide anti-herpes antiviral drugs, ACV [32, 33] is considered a milestone drug due to its excellent selectivity and low toxicity and has been used to effectively treat infections caused by most known HHVs, particularly HSV and VZV. Another acyclic nucleoside drug GCV [34, 35] has been the first-line treatment for HCMV for decades.

Another mechanistically distinct viral polymerase inhibitor is the pyrophosphate (PPi) mimic foscarnet (PFA), which binds to a site similar to but distinct from the PPi binding site of the viral polymerase to block the pyrophosphate exchange [36]. Notably, PFA does not require phosphorylation and thus is kinase-independent.

Although polymerase-targeting nucleos(t)ide analogs and the PPi mimic PFA are largely effective against HHVs, they are limited by dose-related adverse effects and the emergence of drug resistance. In line with expanding the anti-herpes antiviral drug repertoire, efforts in recent years have led to the successful development of three mechanistically novel drug classes: amenamevir (AMNV) and pritelivir (PTV), inhibitors of viral helicase–primase complex, for treating VZV and HSV, respectively; letemovir (LTV), which targets pUL56, a component protein of the

Table 1 Antiviral drugs against HHVs.

Drug class and MOA	Drug name	Note	Year approved	Indication approved
Nucleos(t)ide analogs: phosphorylated intracellularly, incorporated and act as chain terminators	Idoxuridine (IDU)	Thymidine analog. 5-I blocking base pairing.	1963	Topical treatment of herpes simplex keratitis
	Trifluridine (TFT)	Thymidine analog. 5-CF ₃ blocking base pairing	1980	Eye drops for treating keratitis and keratoconjunctivitis caused by HSV
	Brivudine (BVDU)	Thymidine analog. 5-Bromovinyl blocking base pairing	2000	Herpes zoster (VZV) in adult patients
	Vidarabine (ara-A)	Marine spongonucleoside analog	1976	Ointment for treating HSV; herpes zoster (VZV) in AIDS patients
	Aciclovir (ACV)	Acyclic nucleoside analog	1981	Treatment of HSV and VZV infections
	Penciclovir (PCV)	Competitive viral pol inhibition and chain termination	1996	Treatment of zoster (VZV) and genital HSV
	Ganciclovir (GCV)	Competitive viral pol inhibition and chain termination	1988	First-line treatment of CMV infections
	Cidofovir (CDV)	Competitive viral pol inhibition and chain termination	1996	ACV-resistant HSV and GCV-resistant CMV infections
Pyrophosphate mimic	Foscarnet (PFA)	Binding to the PPi binding site and blocking PPi release	1991	ACV-resistant HSV and VZV; GCV-resistant CMV infections
Terminase inhibitor	Letermovir (LTV)	Targeting viral terminase component protein pUL56	2017	Prophylaxis of post-transplant HCMV
Viral kinase inhibitor	Maribavir (MBV)	Inhibition of viral kinase (pUL97)	2021	Treating post-transplant HCMV infections resistant to other drugs
Viral helicase–primase inhibitors	Amenamevir (AMNV)	Inhibition of viral helicase–primase complex	2017	Herpes zoster (shingles)
	Pritelivir (PTV)	Inhibition of viral helicase–primase complex	Phase 3	HSV infections in immunocompromised patients

HCMV terminase complex, for HCMV prophylaxis post stem cell transplants; and maribavir (MBV), an HCMV kinase (pUL97) inhibitor for treating post-transplant HCMV resistant to other drugs.

Antiviral Drugs Targeting Human Immunodeficiency Virus

HIV drug discovery [37, 38] has been particularly successful with the approval of dozens of single agents in the past four decades (Table 2). These drugs, comprising a few distinct drug classes and mechanisms of action, coalesce to a large repertoire for effective antiretroviral therapy (ART), termed the highly active antiretroviral therapy (HAART) [39]. HAART regimens typically consist of two nucleoside reverse transcriptase inhibitors (NRTIs), along with an integrase inhibitor (INSTI), a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Drugs Targeting Reverse Transcriptase

The virally encoded RT [40] is the target of the earliest anti-HIV drug class, nucleos(t)ide reverse transcriptase inhibitors (NRTIs) [41]. Azidothymidine (AZT), initially designed and synthesized by Jerome Horwitz in 1964 [42] as an anticancer drug, was approved by FDA in 1987 as the very first HIV drug [43, 44]. In the following years, numerous other NRTIs were approved, including three other furanonucleoside analogs didanosine (DDI) [45, 46], zalcitabine (DDC) [47], and stavudine (D4T) [48]; the L-nucleoside lamivudine (3TC) [49–51] and emtricitabine (FTC) [52]; the carbocyclic nucleoside abacavir (ABC) [53]; and the acyclic nucleoside phosphate (ANP) tenofovir (TFV) [54]. These nucleos(t)ide drugs are all converted into triphosphate (TP) intracellularly by cellular kinases, recognized and incorporated by RT into viral DNA, and act as obligate chain terminators by virtue of lacking the 3'-OH. Although generally effective against HIV, NRTIs can cause toxicity by inhibiting human mitochondrial DNA polymerase (Pol γ), leading to depletion of mtDNA and mitochondrial dysfunction [55, 56].

Also targeting RT, 4'-ethynyl-2'-fluoro-2'-deoxyadenosine (EFdA) is structurally unique and mechanistically distinct from all other RT inhibitors. As a nucleoside analog, EFdA contains the 3'-OH group, which likely allows more efficient phosphorylation and incorporation. Mechanistically, upon incorporation, EFdA can act as a nonobligate chain terminator as the 4'-ethynyl group distorts the alignment of the primer and the next incoming dNTP, and/or trap RT into a translocation-deficient state where the sliding from N site to P site is inhibited [57, 58]. The latter mechanism renders EFdA the first nucleoside reverse transcriptase translocation inhibitor (NRTTI). Due to the exceptional antiviral potency and the long-lasting PK, EFdA has been developed for PrEP [59].

A conceptually distinct class of RT-targeting drugs is the NNRTIs (Table 2), which allosterically target RT by binding to a largely hydrophobic and well-studied binding pocket ~10 Å away from the active site to induce conformational changes to the active site and distort the positioning of the primer grip to affect its alignment

Table 2 Antiviral drugs against HIV.

Drug class and MOA	Drug name	Note	Year approved
NRTIs: intracellularly phosphorylated, incorporated and act as obligate chain terminators	Zidovudine (AZT)	Furanonucleoside; first HIV drug approved	1987
	Didanosine (DDI)	Furanonucleoside	1991
	Zalcitabine (DDC)	Furanonucleoside	1992
	Stavudine (D4T)	Furanonucleoside	1994
	Lamivudine (3TC)	L-nucleoside	1995
	Abacavir (ABC)	Carbocyclic nucleoside	1998
	Tenofovir (TFV)	ANP. Two prodrug regimens (TDF and TAF) approved	2001
	Emtricitabine (FTC)	L-nucleoside analog	2003
NRTTI: intracellularly phosphorylated, incorporated and inhibits RT translocation	Islatravir (EFdA)	3'-OH present. Long acting	Phase 3
NNRTIs: bind to an allosteric site to impact the conformation of the RT active site	Nevirapine (NVP)	First generation	1996
	Delavirdine (DLV)	First generation; rarely used	1997
	Efavirenz (EFV)	First generation	1998
	Etravirine (ETR)	Second generation	2008
	Rilpivirine (RPV)	Second generation	2011
	Dapivirine (DPV)	Second generation	2022 (Africa)
	Doravirine (DOR)	Second generation	2018
PIs: substrate mimics to inhibit viral protease and block the cleavage of viral precursor proteins	Saquinavir (SQV)	Typically used with PK enhancer RTV	1995
	Ritonavir (RTV)	Used as both an antiviral agent and a PK enhancer (inhibiting CYP3A)	1996
	Indinavir (IDV)	Typically used with PK enhancer RTV	1996
	Nelfinavir (NFV)	Inhibits both HIV-1 and HIV-2	1997
	Lopinavir (LPV)	Used along with PK enhancer RTV	2000
	Atazanavir (ATV)	Inhibits UGT1A1	2003
	Fosamprenavir (FPV)	Prodrug of amprenavir (APV)	2003
	Tipranavir (TPV)	Not a substrate mimic. Used along with PK enhancer RTV	2005
	Darunavir (DRV)	Typically used with PK enhancer RTV. Capable of backbone H-bonding	2006

(Continued)

Table 2 (Continued)

Drug class and MOA	Drug name	Note	Year approved
INSTIs: bind to IN and viral DNA complex (intasome) and selectively inhibit IN strand transfer	Raltegravir (RAL)	First-in-class	2007
	Elvitegravir (EVG)	Enhanced by CYP3A inhibitor Cobicistat	2012
	Dolutegravir (DTG)	Used as a single agent or in FDC along with ABC and 3TC	2013
	Bictegravir (BIC)	Used in FDC along with TAF and FTC	2018
	Cabotegravir (CAB)	Long acting. Approved for PrEP	2021
Entry inhibitors: blocking viral entry at attachment, post-attachment, coreceptor, or fusion	Enfuvirtide (ENF)	Polypeptide (36mer) fusion inhibitor	2003
	Maraviroc (MVC)	Coreceptor CCR5 antagonist	2007
	Ibalizumab	Monoclonal antibody targeting CD4 post-attachment	2018
	Fostemsavir (FTR)	Prodrug of attachment inhibitor temsavir (TMR)	2020
Capsid inhibitor: binds to viral capsid protein (CA) to impact capsid stability and compete against host factors crucial for virus	Lenacapavir (LEN)	Long-acting injectable (every six months)	2022

with the polymerase active site [60, 61]. Since NNRTIs do not interfere with cellular kinases or human mitochondrial DNA polymerase, they are generally better tolerated than NRTIs. Although the FDA approval of the first-generation NNRTIs nevirapine (NVP, 1996), delavirdine (DLV, 1997, discontinued), and efavirenz (EFV, 1998) validated NNRTIs as a clinically important drug class, especially in HAART with the NRTIs, these early NNRTI drugs typically exhibit low generic barrier to resistance [62]. The resistance profile was drastically improved with all second-generation NNRTIs, including FDA-approved etravirine (ETR, 2008) [63], rilpivirine (RPV, 2011) [64], and doravirine (DOR, 2018) [65], as well as dapivirine (DPV) recently approved in Africa for use with monthly vaginal rings (VR) for PrEP [66, 67]. Critical to the success of the second-generation NNRTIs is the rationally designed three-ring pharmacophore to confer high binding flexibility and adaptability [68].

Drugs Targeting Protease

HIV aspartyl protease cuts gag and gag-pol polyproteins to enable the maturation of newly assembled HIV virions. Catalytically, two aspartic acid residues, D25 and D125, are essential for its enzymatic activity [69]. Inhibitors are typically

designed to mimick the transition state of viral substrates using nonhydrolyzable dipeptide (Y/F-P) hydroxyethylene isostere substituted for the scissile amide bond [70, 71]. However, peptidomimetics in general are susceptible to liver metabolizing enzyme CYP3A [72]. The only approved nonpeptidomimetic PI [73], tipranavir (TPV), which features a dihydropyrone ring as the central scaffold, strongly induces CYP3A expression. Therefore, all approved PIs are used in combination with a CYP3A inhibitor, such as low-dose ritonavir (RTV), which is both an antiviral agent and a PK enhancer [74], or Cobicistat (COBI), an analog of RTV and a nonantiviral CYP3A inhibitor [75]. Of the many PIs approved, the first-generation PIs saquinavir (SQV), RTV, indinavir (IDV), and nelfinavir (NFV) exhibit low genetic barrier to the development of broad class resistance, whereas the second-generation PIs lopinavir (LPV), atazanavir (ATV), fosamprenavir (FPV), TPV, and darunavir (DRV) demonstrate much improved resistance profiles.

Drugs Targeting Integrase Strand Transfer

Integration of viral DNA into host DNA is a required and signature step in the replication cycle of retroviruses [76, 77]. The stably maintained integrated proviral DNA in resting CD4+ T cells allows persistent infections and poses a major barrier toward eradication via antiviral therapy. Integration is carried out by the virally encoded integrase (IN), which has two distinct functions: the 3'-processing (3'-P) and the strand transfer (ST). The 3'-P nicks the terminal 3' dinucleotide from viral DNA to generate the free 3' OH, which serves as the nucleophile for the ST where viral DNA is inserted into cellular DNA [78]. In addition, productive HIV integration also entails IN binding to a cellular cofactor, the lens epithelium-derived growth factor (LEDGF)/p75. Although both enzymatic functions [79] and the allosteric binding to LEDGF/p75 [80] have been targeted for the discovery of IN-targeting antivirals, only selective INST inhibitors (INSTIs) have achieved clinical successes, and validated IN as a viable HIV drug target [81]. The chemical matter of selective INSTIs uniquely and invariably features a chelating triad capable of engaging with two Mg^{2+} ions at the DDE active site [82]. Raltegravir (RAL) [83] was the first-in-class INSTI developed which gained FDA approval in 2007. This milestone success was followed by the successful development and approval of four additional INSTIs, elvitegravir (EVG) [84], dolutegravir (DTG) [85], bicitgravir (BIC) [86], and cabotegravir (CAB) [87]. Interestingly, CAB is approved to be used in combination with NNRTI RPV as the first LAI ART option for virologically suppressed adults with HIV-1. In addition, long-acting CAB has the potential for HIV PrEP.

Drugs Targeting Viral Entry

HIV entry consists of three major steps [88]: attachment, coreceptor binding, and fusion, all of which have been successfully targeted by FDA-approved drugs (Table 2). The infection starts with binding of the viral glycoprotein gp120 to the CD4 receptor on host cells. Pharmacologically disrupting this binding

interaction led to the development of recently approved fostemsavir (FTR), the prodrug of attachment inhibitor temsavir [89, 90]. Significantly, since FTR works in a step prior to coreceptor binding, it inhibits both CCR5-tropic and CXCR4-tropic HIV.

Upon attachment, the binding to CD4 causes gp120 conformational changes to allow HIV to stably bind to the CCR5 (R5-tropic) or CXCR4 (X4-tropic) coreceptor, which is a required step for viral entry. The approved HIV drug maraviroc (MVC) [91, 92] is a CCR5 antagonist that binds to a CCR5 transmembrane pocket to allosterically alter the conformation of the extracellular domains to block viral gp120 binding. This specific mechanism also renders MVC ineffective against X4-tropic HIV and necessitates a tropism assay prior to treatment. Although resistance via tropism switch is rare due to large genetic barrier, high-level resistance to MVC was still selected, which is due to viral entry using MVC-bound CCR5 [93]. Alternatively, the outgrowth of the preexisting X4-tropic viral population can also confer resistance to MVC [94].

The sequential binding of the receptor and the coreceptor triggers fusogenic conformational changes in viral gp41 to expose a fusion peptide that inserts into the cellular plasma membrane to initiate fusion. The fusion-targeting enfuvirtide (ENF) was the first approved HIV entry inhibitor [95]. A polypeptide (36mer) derived from HIV-1 gp41 C-terminal heptad repeat (CHR), ENF interferes with CHR interaction with the highly conserved N-heptad repeat (NHR) to inhibit the formation of the required six-helix bundle (6HB) and subsequent viral entry. ENF is not orally available due to the intrinsically unfavorable physicochemical properties of peptides [96], especially enzymatic degradation and poor membrane permeability, and is administered via subcutaneous injection.

Ibalizumab [97, 98] is another HIV entry inhibitor approved. It is a humanized monoclonal antibody and a post-attachment inhibitor. Mechanistically, ibalizumab binds to a conformational epitope on domain 2 of the extracellular portion of CD4, and blocks HIV from binding to the CCR5 or CXCR4 coreceptors. Similar to the attachment inhibitor FTR, ibalizumab is active against both R5-tropic and X4-tropic HIV isolates.

Drugs Targeting Viral Capsid

The multifunctional HIV capsid protein (CA) is the target of the most recently approved HIV drug lenacapavir (LEN) [99]. Mechanistically [100, 101], LEN binds to a pocket at a conserved interface between CA protomers to interfere with the binding of host cofactors essential for multiple phases of the viral replication cycle, including NUP153 and CPSF6, which are required for viral nuclear entry. LEN shows antiviral potency at picomolar concentrations against all subtypes of HIV-1 tested, and exhibits high synergy and no cross-resistance with other classes of HIV drugs. The exceptional antiviral profile, along with the low in vivo systemic clearance and slow-release kinetics from the subcutaneous injection site, renders LEN an excellent LAI drug [102]. Remarkably, LEN is approved to be used via injection every six months.

Antiviral Drugs Targeting Hepatitis B Virus

Hepatitis B virus (HBV) chronically infects an estimated 240–350 million people worldwide and remains a major global health threat [103, 104]. Although an effective vaccine is widely available, each year there are still around 1 million people newly infected. Individuals chronically infected with HBV are at high risk of severe liver diseases typically progressing through fibrosis, cirrhosis, and eventually hepatocellular carcinoma. HBV-associated liver diseases account for approximately 750 000 deaths annually. Fortunately, multiple drugs have been developed and marketed against chronic HBV (Table 3) [105]. Although these drugs rarely lead to functional cure, their lifelong use effectively suppresses HBV replication and reduces the risk of liver cancer. Current HBV drugs consist of two classes (Table 3): the immunomodulatory interferon, including IFN alpha-2b and PegIFN alpha-2a [106]; and direct acting nucleos(t)ide analogs (NAs) targeting reverse transcriptase (RT), the viral polymerase. Similar to HIV, HBV-encoded RT has been successfully targeted by various NAs, including cytidine L-nucleoside analog lamivudine (3TC) [107], adenosine analogs adefovir (AFV) [108] and tenofovir (TFV) [107], guanosine carbocyclic analog entecavir (ETV) [109], and L-thymidine telbivudine (TBV) [110] and its 2'-β-F analog clevudine (CLV) [111]; the latter was approved in South Korea only. Notably, while close analogs AFV and TFV were initially approved as ester prodrugs, the recent ProTide prodrug of TFV, tenofovir alafenamide (TAF) [112, 113],

Table 3 Antiviral drugs against HBV.

Drug class and MOA	Drug name	Note	Year approved
Nucleoside polymerase inhibitors: intracellularly phosphorylated, incorporated and act as chain terminators	Lamivudine (3TC)	L-nucleoside	1998
	Adefovir (AFV) dipivoxil	ANP prodrug	2002
	Entecavir (ETV)	Carbocyclic nucleoside	2005
	Telbivudine (TBV)	Thymidine L-nucleoside	2006
	Tenofovir (TFV) disoproxil fumarate (TDF)	Prodrug of ANP	2008
	Tenofovir (TFV) alafenamide (TAF)	ProTide prodrug of ANP	2016
	Clevudine (CLV)	L-nucleoside; approved in Korea	2006
Interferons (IFNs): immunomodulators	IFN alpha-2b	Three times a week; injection	1991
	PegIFN alpha-2a	Long acting (once weekly, injection)	2005

allows much lower dosing and improved safety profile due to the liver-specific delivery. Interestingly, HBV and HIV share two prominent therapeutic commonalities: (1) many NAs approved for treating HBV are also HIV drugs, including 3TC, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide TAF and (2) these drugs do not cure the infection, presumably because they do not impact the viral reservoirs. Adefovir was also initially being developed as an HIV drug; however, its toxicity at the doses required for systemic usage limited its use, compared to a much lower dose required for a liver-tropic drug. Current efforts in the field are looking to identify a combination regimen that suppresses viral replication, reduces the production of HBV surface antigen, and reactivates an HBV-specific immune response with the hope of achieving high rates of functional cure with a short duration of therapy.

Antiviral Drugs Targeting Hepatitis Delta Virus

Hepatitis D virus (HDV) is a single-stranded (–)-RNA virus whose genome folds into a rod-like structure with no nucleocapsid. HDV requires the presence of HBV to propagate because it uses the HBV surface antigens (HBsAg) to complete its viral coat. It is the HBsAg in the HDV viral coat that is recognized by the sodium taurocholate cotransporter polypeptide (NTCP) receptor on the surface of an hepatocyte facilitating viral entry. The HD antigen (HDAG) expressed as two isoforms (small and large) is the only protein expressed by HDV. Since HDV produces no other proteins, it uses cellular DNA-dependent RNA polymerases to replicate its genome. Post-translational modification of HDAGs modifies their function and therefore enables modulation of the viral life cycle. Coexistence of HDV and HBV leads to more severe liver disease and a more rapid progression to cirrhosis and liver cancer [114, 115].

Current therapies to treat HDV infection consist of pegylated interferon- α (PEG-IFN) and newly introduced bulevirtide (Myrcludex B, BLV), which blocks viral entry (Table 4). Pegylated interferon has shown limited efficacy [116]. However, BLV, which is a myristolated synthetic lipopeptide mimicking the N-terminal region of the pre-S1 domain of HBsAg, has demonstrated promising efficacy and enhanced efficacy has been observed in combination with PEG-IFN [114].

Table 4 Antiviral drugs against HDV.

Drug class and MOA	Drug name	Note	Year approved
Therapeutic protein Innate immune activation	Pegylated interferon- α (PEG-IFN)	Subcutaneous delivery; limited efficacy	Mid-2000s
Myristolated synthetic polypeptide	Bulevirtide (BLV, Myrcludex B)	Inhibits viral entry by blocking the NTCP receptor; only approved by the EMEA in the European Union and not by the US FDA	2020

Antiviral Drugs Targeting Hepatitis C Virus

The hepatitis C virus (HCV) is a liver tropic virus that chronically infects over 75 million individuals worldwide and is a leading cause of chronic liver disease and liver cancer [117]. This (+)-sense RNA virus replicates in the cytoplasm of hepatocytes, does not integrate into the host genome, nor does it appear to leave a reservoir of genetic material in the infected cell [118].

Drugs targeting the hepatitis C virus (HCV) can be classified into two categories: immunomodulators and direct-acting antivirals (Table 5). The first drug developed for curing HCV was the immunomodulator interferon- α (IFN). The evolution of interferon therapies ultimately led to the development of more effective pegylated interferons, PEG-INTRON and PEGASYS. The use of ribavirin (RBV) in conjunction with IFN was shown to increase the cure rates of IFN therapies to 40%; however, significant adverse side effects and genotype coverage limited the use of IFN regimens [119].

The evolution of HCV curative therapies eventually focused on the development of direct-acting antivirals (DAAs) and the elimination of IFN in clinical practice (Table 5). DAA therapeutic development targeted three viral nonstructural proteins, NS3/4a protease, NS5A replication complex protein, and the NS5B RNA-dependent RNA polymerase [22, 120]. The launch of the NS3/4a PIs telaprevir and boceprevir each in combination with IFN not only led to improved cure rates but also added to the undesirable side effect profile already seen with IFN use. Approval of the liver-targeted NS5B polymerase inhibitor sofosbuvir ushered in the era of IFN-free HCV curative therapies with short 8–12-week treatment duration, pan-genotypic profile, high barrier to resistance, minimal side effect profile, and cure rates surpassing 95% [121, 122]. Combinations that included sofosbuvir with either RBV, the NS3/4a PI, simeprevir or NS5A inhibitors, ledipasvir or daclatasvir soon became the regimens of choice for genotypes 1, 2, and 3 HCV patients [123–126]. Eventually, DAA regimens that included combinations of NS5A inhibitors and NS3/4a PIs with or without a non-nucleoside NS5B inhibitor (paritaprevir/ombitasvir/dasabuvir, grazoprevir/elbasvir) were introduced but had limited uptake because of their poor genotype coverage and resistance profile [127, 128]. However, these were eventually surpassed by the highly potent and pan-genotypic regimes sofosbuvir/valpatasvir and glecaprevir/pibrentasvir which dominate the market providing cure rates of over 95% [22, 129, 130]. To address any patients who exhibited breakthrough resistance or relapse, primarily from the NS5A component of these regimens, the triple combination regimen sofosbuvir/valpatasvir/voxilaprevir was introduced [131].

Antiviral Drugs Targeting Acute RNA Respiratory Viruses

Drugs Targeting Human Influenza Viruses

Seasonal flu epidemics are caused by human influenza A virus (IAV) and influenza B virus (IBV). IAVs are classified into many subtypes based on the two viral glycoproteins

Table 5 Antiviral drugs against HCV.

Drug class and MOA	Drug name	Note	Year approved
Therapeutic protein Innate immune activation	Interferon- α (IFN)	Subcutaneous delivery; efficacy was improved with the development of pegylated IFN	1991
	Nucleoside NS5B pol inhibitors: intracellularly phosphorylated, incorporated and act as chain terminators	Ribavirin (RBV)	Additional MOAs include inhibiting IMPDH; inducing Th2 to Th1 switch; lethal mutagenesis; and inhibiting RNA capping. Used in combination with PegIFN
		Sofosbuvir (SOF)	ProTide prodrug; liver-targeted delivery.
Non-nucleoside NS5B pol inhibitor: allosterically inhibit pol	Dasabuvir	Genotype 1; binds to HCV NS5B palm I site	2014
	Beclabuvir (BCV)	Binds to NS5B thumb domain site I	Post marketing
NS3/4 protease inhibitors: bind to the active site inhibit the cleavage of HCV polyproteins	Boceprevir (BOC)	Genotype 1; carbonyl amide warhead; withdrawn in 2015	2011
	Telaprevir (TVR)	Genotype 1; carbonyl amide warhead; discontinued in 2014	2011
	Simeprevir (SMV)	Genotype 1	2013
	Paritaprevir (PTV)	Genotype 1; discontinued in 2018	2014
	Grazoprevir (GZR)	Genotypes 1 and 4	2015
	Asunaprevir (ASV)	Genotype 1	2014
	Voxilaprevir	Pan-genotypic; part of combination with SOF and velpatasvir	2017
	Daclatasvir (DCV)	In combination with ASV; genotype 1	2014
NS5A inhibitors: bind to HCV NS5A to impact genome replication and virion assembly	Ledipasvir (LDV)	In combination with SOF; genotype 1	2014
	Ombitasvir (OBV)	Used in combination therapy for genotype 4	2014
	Elbasvir (EBR)	Used in combination with GZR for genotype 1 or 4	2016
	Velpatasvir (VEL)	Used in combination with SOF for all major genotypes	2020
	Pibrentasvir (PIB)	Used in combination with Glecaprevir for all major genotypes	2017